Evidence map›Paper›PMID 40520557›Full record

ArticleMaterials today. Bio2025

Nerve growth factor-loaded biomimetic prussian blue nanocomplexes for reversing osteoporosis via promoting osteoblast precursor cell proliferation and differentiation.

Yuyi Tian, Yihan Lin, Hao Liu, Xiaona He, Shang Zhu, Luhong Dai, Yuqi Lu, Lihong Liu, Bin Liu

Abstract read
In one paragraph

Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yuyi TianDepartment of Rehabilitation, The Second Xiangya Hospital, Central South University, Changsha, 410011, China.
Yihan LinDepartment of Rehabilitation, The Second Xiangya Hospital, Central South University, Changsha, 410011, China.
Hao LiuDepartment of Rehabilitation, The Second Xiangya Hospital, Central South University, Changsha, 410011, China.
Xiaona HeDepartment of Rehabilitation, The Second Xiangya Hospital, Central South University, Changsha, 410011, China.
Shang ZhuDepartment of Rehabilitation, The Second Xiangya Hospital, Central South University, Changsha, 410011, China.
Luhong DaiDepartment of Rehabilitation, The Second Xiangya Hospital, Central South University, Changsha, 410011, China.
Yuqi LuXiangya School of Medicine, Central South University, Changsha, 410013, China.
Lihong LiuDepartment of Rehabilitation, The Second Xiangya Hospital, Central South University, Changsha, 410011, China.
Bin LiuCollege of Biology, Hunan University, Changsha, 410082, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The fundamental issue of osteoporosis (OP) is osteoblast decrease due to oxidative stress and the subsequent disruption of the osteogenic and osteoclastic dynamic balance. How to promote the proliferation and osteogenic differentiation of osteoblast precursor cells (MC3T3-E1) in an oxidative microenvironment is a great challenge for improving OP. In this study, Prussian blue nanoparticles (PB NPs) were initially functionalized with a polydopamine (PDA) coating. Nerve growth factor (NGF) was subsequently immobilized on the PDA layer, followed by the hybrid membrane coating composed of red blood cell membrane (RBCm) and MC3T3-E1 cell membrane (MC3T3m), thereby constructing a biomimetic Prussian blue nanocomplex loaded with NGF (MPDN NPs). In vitro studies have shown that the nanodrug restored the impaired proliferation viability of MC3T3-E1 cells and inhibit their apoptosis by scavenging reactive oxygen species (ROS), and further cooperate with NGF to promote osteogenic differentiation. In vivo studies have demonstrated that the nanodrug significantly inhibited bone loss and promote bone regeneration in osteoporotic mice. Moreover, this nanodrug with excellent safety both in vitro and in vivo showed the long half-life in the bloodstream and high accumulation in the bone. In summary, this strategy addresses the fundamental issue of decreased osteoblast in OP and offers a novel approach for preventing and treating OP.

Indexed as

Nerve growth factorOsteoblast precursor cellsOsteogenic differentiationOsteoporosisPrussian blue nanoparticlesReactive oxygen species

Identifiers

PMID40520557
PMCPMC12166439

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.